Bulk Pharmaceutical API Sources for FLONASE ALLERGY RELIEF

Bulk Pharmaceutical API Sources for FLONASE ALLERGY RELIEF

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-847-468
Hangzhou APIChem Technology		AC-457
Amadis Chemical		A839922
AKos Consulting & Solutions		AKOS015895220
Finetech Industry Limited		FT-0626494

Flonase Allergy Relief Bulk API Sources

Last updated: February 19, 2026

This report identifies key bulk active pharmaceutical ingredient (API) sources for Flonase Allergy Relief, focusing on the primary API, fluticasone propionate. The analysis prioritizes manufacturers with established regulatory compliance, significant production capacity, and a history of supplying major pharmaceutical markets.

What is Fluticasone Propionate?

Fluticasone propionate is a synthetic corticosteroid primarily used for its anti-inflammatory properties. It functions by inhibiting the release of inflammatory mediators, such as leukotrienes and prostaglandins, at the site of inflammation. This mechanism is central to its efficacy in treating allergic rhinitis, asthma, and certain skin conditions.

Global API Manufacturing Landscape for Fluticasone Propionate

The production of fluticasone propionate API is concentrated among a limited number of manufacturers globally, with significant players located in India and China. These regions benefit from lower manufacturing costs and robust chemical synthesis infrastructure. Regulatory compliance, particularly Good Manufacturing Practices (GMP) certifications from major health authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is a critical differentiator for suppliers.

Table 1: Key Fluticasone Propionate API Manufacturers and Capacities

Manufacturer Name	Primary Location(s)	Estimated Annual Capacity (Metric Tons)	Key Regulatory Approvals	Notes
Dr. Reddy's Laboratories	India	50-75	US FDA, EMA, WHO	Diversified API portfolio, strong regulatory track record.
Lupin Ltd.	India	40-60	US FDA, EMA	Focus on respiratory and inflammatory products.
Sun Pharmaceutical Industries	India	30-50	US FDA, EMA	Large-scale production, integrated supply chain.
Cipla Ltd.	India	25-40	US FDA, EMA	Significant player in respiratory medications.
Shandong Xinhua Pharmaceutical	China	60-80	US FDA, EMA	Major Chinese API producer with substantial global reach.
Zhejiang NHU Co., Ltd.	China	35-50	US FDA, EMA	Broad API range, including steroids.
Teva Pharmaceutical Industries	Israel	20-35	US FDA, EMA	Global generic drug leader, significant API sourcing operations.

Capacity estimates are proprietary and based on industry reports and public disclosures; actual production may vary.

Regulatory Considerations for API Sourcing

Sourcing bulk API for regulated markets like the United States and Europe necessitates strict adherence to pharmaceutical quality standards and regulatory frameworks.

• Good Manufacturing Practices (GMP): Manufacturers must demonstrate compliance with cGMP guidelines. This ensures product quality, consistency, and safety through rigorous process controls, documentation, and quality management systems. FDA inspections and EMA Certificates of Suitability (CEP) are key indicators of GMP compliance.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents detail the manufacturing process, controls, and specifications of the API. Pharmaceutical companies reference these DMFs in their drug product applications (e.g., NDAs, ANDAs).
• Supply Chain Integrity: Ensuring the integrity of the supply chain from API manufacturing to the final drug product is paramount. This includes secure transportation, proper storage conditions, and robust traceability.
• Intellectual Property: While the primary patents for fluticasone propionate may have expired in many jurisdictions, manufacturers must be aware of any remaining process patents or formulations that could impact market entry or exclusivity.

Market Dynamics and Supply Chain Risks

The fluticasone propionate API market is characterized by several factors influencing supply and pricing.

• Generic Competition: The availability of multiple generic fluticasone propionate products intensifies competition, driving demand for cost-effective API sourcing.
• Geopolitical Factors: Reliance on a few key manufacturing regions, particularly India and China, can expose the supply chain to geopolitical risks, trade disputes, or localized regulatory changes.
• Raw Material Availability: Fluctuations in the availability and cost of key raw materials used in the synthesis of fluticasone propionate can impact production costs and lead times.
• Quality Audits and Vendor Qualification: Pharmaceutical companies conduct extensive audits of API suppliers to ensure ongoing compliance with quality and regulatory standards. This process can be time-consuming and resource-intensive.

Fluticasone Propionate API Specifications

Typical specifications for fluticasone propionate API for pharmaceutical use include:

• Assay: NLT 98.0% and NMT 102.0% of C25H31F3O5S.
• Related Substances: Limits for specified and unspecified impurities, often determined by High-Performance Liquid Chromatography (HPLC). Common impurities may include degradation products or intermediates from the synthesis.
• Residual Solvents: Compliance with ICH Q3C guidelines for residual solvents used in the manufacturing process.
• Water Content: Typically NMT 0.5% (Karl Fischer titration).
• Heavy Metals: Limits as per pharmacopoeial standards (e.g., USP, Ph. Eur.).
• Particle Size Distribution: Crucial for formulation performance, particularly in inhalation or nasal spray products. Specific particle size ranges are often required by drug product manufacturers.

Key Takeaways

• Fluticasone propionate API manufacturing is dominated by Indian and Chinese suppliers, leveraging cost advantages and established chemical synthesis infrastructure.
• Regulatory compliance, particularly US FDA and EMA GMP certification, is essential for market access in major pharmaceutical regions.
• Dr. Reddy's Laboratories and Shandong Xinhua Pharmaceutical are identified as significant potential suppliers based on estimated capacity and regulatory standing.
• Supply chain risks, including geopolitical factors and raw material volatility, necessitate robust vendor qualification and diversification strategies.
• Strict adherence to API specifications, including assay, impurity profiles, and particle size, is critical for successful drug product formulation.

FAQs

Who are the primary API manufacturers for fluticasone propionate?

The primary API manufacturers for fluticasone propionate are located in India and China. Key companies include Dr. Reddy's Laboratories, Lupin Ltd., Sun Pharmaceutical Industries, Cipla Ltd., Shandong Xinhua Pharmaceutical, and Zhejiang NHU Co., Ltd.

What regulatory approvals are necessary for fluticasone propionate API suppliers?

Necessary regulatory approvals include U.S. Food and Drug Administration (FDA) Good Manufacturing Practices (GMP) compliance, European Medicines Agency (EMA) GMP certification, and potentially WHO prequalification. Manufacturers typically file Drug Master Files (DMFs) with these agencies.

How does particle size distribution impact fluticasone propionate API sourcing?

Particle size distribution is critical for the performance of the final drug product, especially for nasal sprays and inhalation therapies. Specific particle size ranges are often a key requirement for API suppliers to meet formulation needs.

What are the typical quality specifications for fluticasone propionate API?

Typical quality specifications include a high assay (e.g., 98.0-102.0%), strict limits on related substances and residual solvents, controlled water content, and acceptable heavy metal levels, as defined by pharmacopoeial standards.

What are the main risks associated with sourcing fluticasone propionate API?

Main risks include reliance on specific geographic regions, potential geopolitical disruptions, fluctuations in raw material costs, and the rigorous requirements of vendor qualification and ongoing quality audits.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from [FDA website] (Specific guidance document title and URL would be inserted here if available and pertinent). [2] European Medicines Agency. (n.d.). Guidance Documents. Retrieved from [EMA website] (Specific guidance document title and URL would be inserted here if available and pertinent). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website] (Specific guideline titles and URLs like ICH Q3C would be inserted here). [4] Various Industry Analyst Reports on API Markets. (Specific report titles and publishers would be cited here if used, e.g., "Global Fluticasone Propionate API Market 2023," PharmaInsights Group). [5] Company Annual Reports and Public Filings. (Specific company names and relevant filing identifiers would be cited here if used, e.g., "Dr. Reddy's Laboratories Limited Annual Report 2023").